ID   U-CH7
AC   CVCL_IR23
SY   UCH7
DR   ATCC; CRL-3404
DR   Cosmic; 2663859
DR   GEO; GSM1673853
DR   GEO; GSM1673854
DR   Wikidata; Q54973620
RX   PubMed=26183925;
RX   PubMed=27102572;
RX   PubMed=28515451;
WW   Info; Chordoma Foundation; -; https://www.chordomafoundation.org/researchers/disease-models/u-ch7/
CC   Doubling time: 7 days (PubMed=26183925); 8 days (Chordoma Foundation).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Bone, sacrum; UBERON=UBERON_0003690.
ST   Source(s): ATCC=CRL-3404; PubMed=26183925; PubMed=27102572
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D10S1248: 13
ST   D12S391: 15,19
ST   D13S317: 10 (ATCC=CRL-3404; PubMed=27102572)
ST   D13S317: 10,12 (PubMed=26183925)
ST   D16S539: 10,12
ST   D18S51: 16
ST   D19S433: 13,14
ST   D1S1656: 17.3
ST   D21S11: 30,33.2
ST   D22S1045: 15
ST   D2S1338: 23
ST   D2S441: 10,14
ST   D3S1358: 17
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 14,16
ST   FGA: 22,24
ST   Penta D: 12,13
ST   Penta E: 12,15
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 11
//
RX   PubMed=26183925; DOI=10.1158/0008-5472.CAN-14-3270;
RA   von Witzleben A., Goerttler L.T., Marienfeld R., Barth H., Lechel A.,
RA   Mellert K., Bohm M., Kornmann M., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Flanagan A.M., Moller P., Bruderlein S., Barth T.F.E.;
RT   "Preclinical characterization of novel chordoma cell systems and their
RT   targeting by pharmocological inhibitors of the CDK4/6 cell-cycle
RT   pathway.";
RL   Cancer Res. 75:3823-3831(2015).
//
RX   PubMed=27102572; DOI=10.1002/path.4729; PMCID=PMC4922416;
RA   Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H.,
RA   Zuercher W.J., Turlais F., Ye H.-T., Leite A.P., Smith J.A., Leithner A.,
RA   Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R.,
RA   Strauss S.J., Pillay N., Flanagan A.M.;
RT   "EGFR inhibitors identified as a potential treatment for chordoma in a
RT   focused compound screen.";
RL   J. Pathol. 239:320-334(2016).
//
RX   PubMed=28515451; DOI=10.1038/s41598-017-02174-5; PMCID=PMC5435709;
RA   Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B.,
RA   von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Wirtz C.R., Moller P., Mellert K.;
RT   "HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and
RT   sacral chordomas.";
RL   Sci. Rep. 7:2032-2032(2017).
//